Galmed Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary

Eocene

02/05/2022 14:31

* Galmed Pharmaceuticals Ltd  GLMD.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 30 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Galmed Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Galmed Pharmaceuticals Ltd shares had risen by 4.4% this
quarter and lost 8.8% so far this year.
    * The company reported a quarterly loss of $7.45 million.
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 2 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated